Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalbuphine extended release - Trevi Therapeutics

Drug Profile

Nalbuphine extended release - Trevi Therapeutics

Alternative Names: Haduvio; Nalbuphine ER; Nalbuphine extended-release; PW-4142; T 111

Latest Information Update: 02 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Penwest Pharmaceuticals
  • Developer Endo Pharmaceuticals; MentiNova; Rutgers; Trevi Therapeutics
  • Class Antitussives; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prurigo nodularis; Pruritus
  • Phase II Cough
  • Preclinical Drug-induced dyskinesia
  • Discontinued Pain

Most Recent Events

  • 02 Jun 2020 Trevi Therapeutics completes a phase I trial evaluating abuse potential in Canada (NCT04018664)
  • 07 Feb 2020 Trevi Therapeutics re-initiates a phase I pharmacokinetic trial for Pruritus (associated with liver disease) in USA (NCT04020016)
  • 08 Aug 2019 Phase-II clinical trials in Cough in United Kingdom (PO) (NCT04030026)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top